Alchemi combines cutting-edge AI with deep scientific expertise to help development teams bring therapies to market faster.

Our Mission

Solving the R&D crisis

It takes over a decade and more than $2 billion to bring a new drug to market. We founded Alchemi to change this.

We're creating a future where AI will work in tandem with scientists, accelerating drug development. In doing so we can reduce timelines, lower drug costs, and increase access to life-saving medicines.

Meet Our Team

Leadership

Tom Mulvey

Former life science investor at Vitruvian Partners, focused on partnering with CROs and CDMOs. Operating experience at CAR-T manufacturing pioneer Ori Biotech and gene therapy developer Lexeo Therapeutics. MBA from Harvard Business School.

Anuj Chadha

Former senior software engineer at Vecna Robotics, researcher at NASA. Focused on AI at Caltech. Investor at Blueyard Capital. MBA from Harvard Business School.

Caroline Atyeo, PhD

Former Staff Fellow of AI at the FDA. Research experience with Moderna as a Senior Scientist focused on infectious disease. PhD in Virology from Harvard Medical School.

Mikael Dolsten, PhD

Former CSO of Pfizer. Chairs BenchSci's board. Sits on the boards of Chai Discovery and Agilent, and advises Formation Bio, Blackstone, ARCH and Google Ventures.

Advisory Board

Ben Cons, PhD

Advisor

Former EVP at IQVIA, former Chair of Castor (ML platform for clinical trials), Special Partner at Vitruvian Partners. PhD in Pharmacology.

Mark E. Arnold, PhD

Advisor

Former Director of Science at Labcorp, former Executive Director at Bristol Myers Squibb, former Chair of the AAPS Scientific Advisory Committee. PhD in Pharmacology.

John Ludwig, PhD

Advisor

Former Pfizer executive in multiple senior leadership roles, most recently SVP Pharmaceutical Sciences & Global Clinical Supply. Member of Danaher's Scientific Advisory Board.